Recruitment remedy? Antidote teams with direct-to-patient lab to screen clinical trial participants

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/luchschen)
(Image: Getty/luchschen)

Related tags: Clinical trial, Patient recruitment

The digital health company Antidote Technologies is partnering with PWNHealth, a virtual care company that provides direct-to-patient (DTP) lab services.

Antidote Technologies connects patients and clinical trial sponsors to help accelerate research, explained Tom Krohn, chief development officer, Antidote.

The combined services will provide researchers with access to potential clinical trial participants via Antidote's partner network as well as lab-validated referrals through PWNHealth's physician network and more than 40 lab partners.

“Antidote approached PWN Health to explore options to leverage their direct-to-patient lab service offering in the context of clinical research,”​ Krohn told us, adding that the companies immediately “found synergy”​ and moved forward with the partnership.

“Our goal is to better serve the stakeholders in clinical research through advanced pre-screening approaches that incorporate labs,”​ Krohn explained. “This will help sponsors, patients and research sites together.”

The partnership addresses the increasing inclusion of biomarkers as an eligibility criterion for participation in clinical trials.

“In clinical research, we’re seeing more precision medicine and greater targeting of patient populations, where labs, such as genetic markers and other biomarkers, are key eligibility criteria,”​ said Krohn. 

The partnership is open-ended and focuses on shared value for all stakeholders, he explained: “Precision medicine and research through labs is not one-off need, but a general trend.”

As for next steps, Krohn said some project work is about to launch and additional projects are being explored.

Antidote also recently announced an alliance with phaware, a pulmonary hypertension (PH) advocacy organization. The strategic partnership that will provide patient recruitment services to pharmaceutical companies and contract research organizations (CROs) conducting clinical trials in chronic lung diseases.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us


View more